Skip to main content
NASDAQ:MDNA

Medicenna Therapeutics Stock Forecast, Price & News

$3.41
+0.17 (+5.25 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.23
$3.45
50-Day Range
$3.24
$4.28
52-Week Range
$3.14
$6.84
Volume44,331 shs
Average Volume206,347 shs
Market Capitalization$182.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39
30 days | 90 days | 365 days | Advanced Chart
Receive MDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Medicenna Therapeutics logo

About Medicenna Therapeutics

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDNA
CUSIPN/A
CIKN/A
Phone416-648-5555
Employees7
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.77 per share

Profitability

Net Income$-6,220,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$182.60 million
Next Earnings Date5/21/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.70 out of 5 stars

Medical Sector

1296th out of 2,044 stocks

Pharmaceutical Preparations Industry

561st out of 769 stocks

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Medicenna Therapeutics (NASDAQ:MDNA) Frequently Asked Questions

Is Medicenna Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock.
View analyst ratings for Medicenna Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Medicenna Therapeutics?

Wall Street analysts have given Medicenna Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medicenna Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Medicenna Therapeutics?

Medicenna Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 268,600 shares, an increase of 45.2% from the March 15th total of 185,000 shares. Based on an average daily trading volume, of 218,900 shares, the short-interest ratio is currently 1.2 days. Approximately 0.7% of the shares of the company are sold short.
View Medicenna Therapeutics' Short Interest
.

When is Medicenna Therapeutics' next earnings date?

Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Medicenna Therapeutics
.

What price target have analysts set for MDNA?

4 brokerages have issued twelve-month target prices for Medicenna Therapeutics' stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate Medicenna Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 193.3% from the stock's current price.
View analysts' price targets for Medicenna Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:
  • Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 64, Pay $328.28k)
  • Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 64, Pay $255.51k)
  • Ms. Elizabeth Williams C.A., CPA, CPA, CA, CFO & Corp. Sec. (Age 43, Pay $179.72k)
  • Dr. John H. Sampson M.D., Ph.D., MBA, Chief Clinical Advisor
  • Dr. Martin Bexon M.D., Head of Clinical Devel.
  • Dr. Samuel R. Denmeade, Scientific Advisor

Who are some of Medicenna Therapeutics' key competitors?

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA."

Who are Medicenna Therapeutics' major shareholders?

Medicenna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Board of Trustees of The Leland Stanford Junior University (1.80%), Renaissance Technologies LLC (0.26%), Geode Capital Management LLC (0.04%) and JPMorgan Chase & Co. (0.02%).

Which major investors are buying Medicenna Therapeutics stock?

MDNA stock was purchased by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Geode Capital Management LLC, Renaissance Technologies LLC, and JPMorgan Chase & Co..

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately $3.41.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics has a market capitalization of $182.60 million. The company earns $-6,220,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does Medicenna Therapeutics have?

Medicenna Therapeutics employs 7 workers across the globe.

What is Medicenna Therapeutics' official website?

The official website for Medicenna Therapeutics is www.medicenna.com.

Where are Medicenna Therapeutics' headquarters?

Medicenna Therapeutics is headquartered at 200-1920 Yonge Street, Toronto A6, M4S 3E2.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The company can be reached via phone at 416-648-5555 or via email at [email protected]


This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.